Form 4 Filing for BridgeBio Pharma, Inc.

This filing details stock transactions by Neil Kumar, CEO of BridgeBio Pharma, Inc. On May 21, 2026, Mr. Kumar sold a total of 23,853 shares of common stock. These sales were executed under a Rule 10b5-1 trading plan. The transactions included various weighted average prices, ranging from $66.81 to $70.97 per share. Following these transactions, Mr. Kumar directly holds 243,327 shares. Additionally, he has indirect ownership of 555,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,358,447 shares through the Kumar Haldea Revocable Trust, where he serves as a co-trustee.